Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia

Journal of Medical Economics

Volumn 11, Issue 4, 2008, Pages 571-584

  Breitscheidel, Lusine ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Kendle International Inc   (Germany)

Author keywords

Chronic myeloid leukaemia; Cost utility; Imatinib; Markov; Stem cell transplantation

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DONOR; DRUG COST; GERMANY; GROUPS BY AGE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION; ALLOTRANSPLANTATION; CHRONIC DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; MYELOID LEUKEMIA; PROBABILITY; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; GERMANY; HUMANS; LEUKEMIA, MYELOID; MARKOV CHAINS; PIPERAZINES; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67449102723     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802354683     Document Type: Article

References (35)

1. Schmoll H-J, Wolf H-H. Leukemia. Accessed 24th November 2006 from: http://www.krebsgesellschaft.de/db-leukaemie,4221.htm
2. Ruiz-Argüelles G, Tarin-Arzaga L, Gonzalez-Carillo et al. Therapeutic choices in patients with Ph-positive CML living in México in the tyrosine kinase inhibitor era: SCT or TKI? Bone Marrow Transplant 2008; 42: 23-28.
3. Giralt S, Arora M, Goldman J et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British Journal of Haematology 2007; 137: 461-467. (Pubitemid 46698285)
4. Gratwohl A, Brand R, Apperley J et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: allogeneic hematopoietic stem cell transplantation for chronic myeloid leukaemia in Europe 2006: transplant activity, long-term data and current results. Haematologica 2006; 91: 513-521.
5. Gratwohl A, Baldomero H, Labar B et al. Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croatian Medical Journal 2004; 45: 689-694.
6. Ruiz-Argüelles G, Gömez-Almaguer D, López- Martínez B et al. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukaemia. Haematologica 2002; 87: 894-896. (Pubitemid 34851567)
7. Ruiz-Argüelles G, Gömez-Almaguer D, Morales-Toquero A et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph (+) chronic myelogenous leukaemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LA-COHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043-1047. (Pubitemid 43078131)
8. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820. (Pubitemid 44394987)
9. Lungen M, Dredge B, Rose A et al. Using diagnosis-related groups: the situation in the United Kingdom National Health Service and in Germany. European Journal of Health Economics 2004; 49: 287-289. (Pubitemid 40543179)
10. Kassenarztliche Bundesvereinigung (KBV). Einheitlicher Bewertungsmaβstab (EBM) für ärztliche Leistungen 2005. Deutscher Ärzte-Verlag, 2005.
11. Skrepnek G, Ballard E. Cost-efficacy of Imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005; 25: 325-334. (Pubitemid 40300319)
12. Druker B, Guilhot F, O'Brien S et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine 2006; 355: 2408-2417. (Pubitemid 44903745)
13. DeAngelo D, Hochnerg E, Alyea E et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clinical Cancer Research 2004; 10: 5065-5071. (Pubitemid 39099780)
14. Hess G, Bunjes D, Siegert W et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospecive phase II open-label multicenter study. Journal of Clinical Oncology 2005; 23: 7583-7593. (Pubitemid 46291822)
15. Guilhot F, Roy L, Millot F. Update of first-line imatinib therapy in chronic phase chronic myeloid leukemia. Hematology 2006; 2: 93-97.
16. Gratwohl A, Hermans J, Goldman J et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092. (Pubitemid 28448513)
17. Goker H, Haznedaroglu I, Chao N. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology 2001; 29: 259-277. (Pubitemid 32223460)
18. Loughran T, Sullivan K, Morton T et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 228-234. (Pubitemid 20220815)
19. Gratwohl A, Brand R, Apperley J et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886. (Pubitemid 35396852)
20. Martinez C, Gomez V, Tomas J et al. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Transplante Hemopoyético). Bone Marrow Transplant 2005; 36: 301-306.
21. Carreras E, Tomas J, Sanz G et al. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. Haematologica 2000; 85: 530-538. (Pubitemid 30428578)
22. Berger U, Engelich G, Reiter A et al. Imatinib and beyond-the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon- alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Annals of Hematology 2004; 83: 258-264.
23. G-DRG Fallpauschalenkatalog 2005. Baumann Verlag.
24. Rote Liste Service GmbH. Rote Liste 2005. Editio Cantor.
25. Reed S, Anstrom K, Ludmer J et al. Cost-effectiveness of imatinib versus interferon-a plus low-dose cytarabine forpatients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004; 101: 2574-2583. (Pubitemid 39532287)
26. Lee S, Kuntz K, Horowitz M et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Annals of Internal Medicine 1997; 127: 1080-1088. (Pubitemid 28012077)
27. Mauro M. Management of newly diagnosed CML: an update from ASH 2005. Accessed September 2006 from: http://www.hememalignancies.com/ash-2005/pdf/ mauro.pdf
28. Hoelzer D. Projekt 23: ökonomische evaluation der Leuk̈mietherapie. Accessed December 2005 from: http://www.kompetenznetz- leukaemie.de/kn-home/Projekt/Evaluation.php3
29. Hochhaus A, Hehlmann R. Chronische Myeloische Leuk̈mie. Biologie -Klinik - Diagnostik-Therapie. Uni-Med Verlag, Bremen 2001.
30. Warren E, Ward S, Gordois A et al. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukaemia in the chronic phase. Clinical Therapy 2004; 26: 1924-1933. (Pubitemid 40089505)
31. Gordois A, Scuffham, Warren E et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer 2003; 89: 634-640. (Pubitemid 37076165)
32. Dalziel K, Round A, Garside R et al. Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005; 23: 515-526. (Pubitemid 40994139)
33. Garrison L. The ISPOR Good Practice Modeling Principles-a sensible approach: be transparent, be reasonable. Value in Health 2003; 6: 6-8. (Pubitemid 36228344)
34. Stapff M. [Clinical research in DRG-era]. In German. Deutsche Zeitschrift für Klinische Forschung 2004; 9/10: 16-25.
35. Roeder N, Franz D, Glocker S. [Oncology: hospital funding in Germany. Problems and opportunities]. In German. Onkologe 2005; 11: 173-189.